Skip to main content

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

NCT04432090

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

Associated Conditions

Type 1

Principal Investigator

Sponsor

AdventHealth

People with type 1 diabetes are at high risk of developing hypoglycemia because of insulin treatment and because their body is less effective at increasing the levels of sugar in their blood when it is low. In this research study we will test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point. Study Duration: 2-3 Months Age: 20-60 Years Old Sex: Male and Female Conditions/Eligibility: Type 1 Diabetes in General Good Health Healthy Participant Study Procedures: Blood and Urine Collection EKG Study Medication Continuous Glucose Monitoring Compensation: Up to $3075.00 Please call (407)303-7193 or fill out the Contact Form below for more information.

This study is currently enrolling.


Interested in Participating?

Please call (407) 303-7193 or fill out the Contact Form below for more information.